Eli Lilly Launches 50% Discounted Zepbound Vials in 2.5 mg and 5 mg Doses

Aug 27, 2024, 11:29 AM

Eli Lilly has announced the release of single-dose vials of its weight-loss drug Zepbound (tirzepatide) in the United States, aimed at expanding access and addressing supply constraints. The new vials are available in 2.5 mg and 5 mg doses, priced at $399 and $549 for a four-week supply, respectively. This represents a 50% discount compared to the previous cost of injection pens. The move is intended to provide more affordable options for patients without insurance coverage and is distributed through Lilly's direct-to-consumer platform, LillyDirect. This initiative is also seen as a response to pharmacies compounding the drug and aims to challenge telehealth companies offering compounded versions. The announcement has impacted the stock of companies like Hims & Hers Health, which saw a decline following the news.